Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115823) titled 'Ferric Carboxymaltose (FCM) for the Treatment of Anemia Following Total Hip Arthroplasty: A Single-Center, Randomized, Open-Label, Placebo-Controlled Superiority Study' on Dec. 31, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Changzhou Second People's Hospital Affiliated to Nanjing Medical University
Condition:
Total hip replacement
Intervention:
FCM Group:Postoperative use of FCM injection
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: FCM Group:118;Blank control group:118;
Countries of Recruitment:
China
T...